Published Technical Disclosure Archive

Enhanced Human Cytomegalovirus GB Polypeptide for Specialized Applications

Publication ID: 24-11857622_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Enhanced Human Cytomegalovirus GB Polypeptide for Specialized Applications,” Published Technical Disclosure No. 24-11857622_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857622_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,622.

Summary of the Inventive Concept

The inventive concept adapts the human cytomegalovirus GB polypeptide for high-security bioresearch facilities, disaster relief efforts, extreme weather conditions, high-containment laboratories, and remote or isolated research stations, providing enhanced stability, thermal stability, and binding properties.

Background and Problem Solved

The original patent disclosed engineered mutants of human cytomegalovirus glycoprotein B (gB) protein with improved stability and immunogenicity. However, these mutants may not be suitable for specialized applications requiring high-security, extreme weather conditions, or remote research settings. The new inventive concept addresses these limitations by introducing novel mutations and adaptations for these niche environments.

Detailed Description of the Inventive Concept

The enhanced human cytomegalovirus GB polypeptide comprises at least two amino acid mutations, including at least one engineered disulfide mutation and at least one additional mutation. These mutations provide improved stability in prefusion form, thermal stability, and binding properties to prefusion-specific antibodies. The inventive concept can be implemented in various forms, including systems for high-security bioresearch facilities, methods for disaster relief efforts, and systems for extreme weather conditions, high-containment laboratories, and remote or isolated research stations.

Novelty and Inventive Step

The new claims introduce novel mutations and adaptations that are non-obvious and provide significant advantages over the original patent. The combination of engineered disulfide mutations and additional mutations for enhanced stability, thermal stability, and binding properties is a key inventive step.

Alternative Embodiments and Variations

Alternative embodiments may include different combinations of mutations, varying the number and type of engineered disulfide mutations and additional mutations. Variations may also include different forms of the inventive concept, such as expression systems, vaccine formulations, or diagnostic tools.

Potential Commercial Applications and Market

The enhanced human cytomegalovirus GB polypeptide has significant commercial potential in the biotechnology and pharmaceutical industries, particularly in the development of vaccines and diagnostic tools for high-security, disaster relief, and extreme weather condition applications.

CPC Classifications

SectionClassGroup
A A61 A61K39/245
C C07 C07K14/045
C C12 C12N7/00
C C12 C12N2710/16134

Field of Art

Virology, molecular biology, and protein engineering, specifically focused on cytomegalovirus glycoprotein B (gB) modifications and vaccine development

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with advanced degrees in molecular biology or virology, experienced in protein engineering, viral protein modification techniques, and vaccine design, familiar with protein stability optimization and mutation strategies

Obviousness Rationale

A person of ordinary skill would recognize that the PTD's variations represent predictable extensions of the source patent's core teachings about cytomegalovirus gB protein mutations. The disclosed modifications follow established protein engineering principles of enhancing stability, thermal resistance, and antibody binding through targeted amino acid substitutions. The systematic approach of combining disulfide mutations with additional modifications represents a routine optimization strategy well within the capabilities of a skilled practitioner in the field.

Obvious Combinations & Variations

Source Patent Element
Wild-type CMV gB protein with potential for mutation
PTD Variation
Engineered mutant with multiple amino acid mutations including disulfide and additional mutations
Obviousness Reasoning
Routine protein engineering technique of introducing multiple mutations to enhance protein characteristics, representing a predictable variation using known molecular biology techniques
Source Patent Element
Prefusion-specific stability measurement methods
PTD Variation
Application of stability measurements to specialized research environments like high-security facilities and disaster relief
Obviousness Reasoning
Extending known protein characterization techniques to novel application contexts represents a standard design choice for skilled researchers
Source Patent Element
Towne strain wild-type CMV gB sequence
PTD Variation
Mutations targeting enhanced thermal stability and antibody binding across different research environments
Obviousness Reasoning
Systematic optimization of viral protein characteristics through targeted mutations is a predictable approach in protein engineering
Source Patent Element
Basic disulfide mutation strategies
PTD Variation
Combination of disulfide mutations with additional mutations for enhanced trimerization and stability
Obviousness Reasoning
Combining known mutation techniques to improve protein characteristics represents a standard problem-solving approach in molecular biology
Source Patent Element
Initial prefusion-specific antibody binding concepts
PTD Variation
Enhanced binding properties for specialized research environments
Obviousness Reasoning
Incremental improvements in protein binding characteristics through targeted mutations are expected outcomes in protein engineering
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857622 and the principles of protein engineering, the variations disclosed in this published technical disclosure would be considered obvious to a person having ordinary skill in the art. The systematic modifications to cytomegalovirus glycoprotein B, including multiple amino acid mutations and targeted stability enhancements, represent predictable extensions of existing knowledge in viral protein modification techniques.

Original Patent Information

Patent NumberUS 11,857,622
TitleHuman cytomegalovirus GB polypeptide
Assignee(s)Pfizer Inc.